Cobra Biomanufacturing offers contract manufacturing services to the biopharmaceutical industry, specifically for use in preclinical to Phase III clinical trials. The company helps its global clients navigate through regulatory requirements while designing and manufacturing novel proteins, viruses, and other cell products. Cobra uses mammalian and microbial host cells for numerous therapeutic protein developments. It also provides a range of DNA maintenance technology, such as its antibiotic-free maintenance system (ORT) and chromosomal modification technology (Xercise). CEO David Thatcher, who joined the company in 1994 as its second employee, stepped down in 2008; he was replaced by COO Simon Saxby.